Results 21 to 30 of about 67,365 (299)
Glucagon‐like peptide‐1 receptor expression in the human eye [PDF]
Diabetes, Obesity and Metabolism, 2018 Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs placebo.
Josephine B. Hebsgaard +5 more
openaire +4 more sources
Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2009 The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be used as specific targets for in vivo receptor radiolabeling.The objective of the study was to test ...
Christ, Emanuel +9 more
openaire +4 more sources
Neural Regeneration Research, 2019 Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj +1 more source
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
International Journal of Endocrinology, 2015 The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang +4 more
doaj +1 more source
Neural Regeneration Research, 2020 Glucagon-like peptide-1 receptor has anti-apoptotic, anti-inflammatory, and neuroprotective effects. It is now recognized that the occurrence and development of chronic pain are strongly associated with anti-inflammatory responses; however, it is not ...
Shan-Shan Cui +4 more
doaj +1 more source
Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]
Electronic Physician, 2013 :Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes.Methods: This was a quasi-experimental study. The population was consisted
Roja Daliri +3 more
doaj +3 more sources
Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists
Endocrinology Research and Practice, 2022 Glucagon-like peptide-1 is the most potent incretin secreted from the intestinal tract. It is synthesized by L-cells in the jejunum and distal ileum of the gastrointestinal system.
Dilek Tüzün
doaj
Physiological Reports, 2017 Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn +4 more
doaj +1 more source
GLP1R rs3765467 Polymorphism Is Associated with the Risk of Early Onset Type 2 Diabetes
International Journal of Endocrinology, 2023 Objective. To investigate the relationship between glucagon-like peptide-1 receptor gene polymorphisms and susceptibility to early onset type 2 diabetes. Methods.
Yunyun Fang +7 more
doaj +1 more source
Journal of Diabetes Investigation, 2022 Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita +8 more
doaj +1 more source